Fig. 3
CRBP-1 regulates cancer stemness properties of HCC. (A) Representative images of tumorspheres formed by CRBP-1 overexpressed PLC/PFR/5 and Huh7 cells as well as control ones. (B) Cell viability of CRBP-1 overexpressed PLC/PFR/5 cells and control ones after treated with different concentrations of sorafenib for 48 h. All data shown represent the mean ± SD from three independent experiments. IC50 values were calculated from dose-response curves. (C) qPCR analysis of the expression of cancer stem cell markers including CD133, SOX2, and OCT4 in CRBP-1 overexpressed PLC/PRF/5 cells and control cells. Data shown for represent the mean ± SD from three independent experiments. (D) Western-blot analysis of the expression of cancer stem cell markers including CD133, OCT4, SOX2, CD90, and EpCAM in CRBP-1 overexpressed PLC/PRF/5 and Huh7 cells as well as control cells. (E) Western-blot analysis of the expression of cancer stem cell markers including CD133, SOX2, and OCT4 in CRBP-1 overexpressed PLC/PRF/5 CD133+ cells and CD133− cells. (F) Representative images of tumorspheres formed by CRBP-1 overexpressed PLC/PFR/5 CD133+ cells and control CD133+ cells